INS and type 1 diabetes mellitus: Finally, pramlintide, a synthetic analogue of human amylin, is the only FDA-approved therapy for T1D (Childs 2006), and it has been shown to reduce HbA1c, daily insulin doses, and postprandial glucose concentrations, with a concomitant modest effect on body weight (Ratner et al. 2004).